Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1402836-58-1
Formula :	C₁₈H₂₂N₂O
M.W :	282.38
SMILES Code :	OC(C1CCCCC1)CC(C2=C3C=CC=C2)N4C3=CN=C4
Synonyms :	NLG919; GDC-0919 analogue; GDC-0919
MDL No. :	MFCD26142661
InChI Key :	YTRRAUACYORZLX-UHFFFAOYSA-N
Pubchem ID :	66558287

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P261-P280-P305+P351+P338

CTLL-2 cells	100 µM	24 hours	Increased IL-2 secretion by approximately 80%	Nat Commun. 2025 Jan 15;16(1):687.
PANC02 cells	750 ng/mL	5 hours	Evaluate the cellular uptake capability of PGEM carrier	Acta Biomater. 2020 Apr 1;106:289-300.
CT26 colorectal tumor cells	1 µM	24 hours	Evaluate cytotoxicity of HCNSP and HCNCP, results showed cell viability over 80%	Adv Sci (Weinh). 2020 Feb 25;7(8):1903332.
CT26 murine colorectal tumor cells	4.0 μg/mL	24 hours	Confirmed the inhibitory effect of NJ NPs on IFN-γ-induced IDO-1 activity, demonstrating a significant reduction in the Kyn/Trp ratio.	Acta Pharm Sin B. 2022 Jun;12(6):2695-2709.
4T1 murine breast tumor cells	10 µM	24 hours	Evaluated the photoactivity and ROS generation of PHPNJ NPs, showing significantly increased ROS production under acidic conditions (pH 6.5).	Acta Pharm Sin B. 2022 Jun;12(6):2695-2709.
MDA-MB-231 cells	100 µM	24 hours	Induced ICD, reduced proportion of Tregs among CD4+ T cells	Nat Commun. 2025 Jan 15;16(1):687.
4T1 cells	100 µM	24 hours	Induced immunogenic cell death (ICD), increased ATP release by 5.2-fold, HMGB1 release by 2.4-fold, and CRT surface exposure by ~30%	Nat Commun. 2025 Jan 15;16(1):687.
B16 tumor cells	50 µM	24 hours	Evaluate the cytotoxicity of NCSNPs on B16 tumor cells and their effect on inducing pyroptosis. Results showed that NCSNPs significantly induced pyroptosis and inhibited tumor cell proliferation.	Adv Sci (Weinh). 2024 May;11(20):e2305382.
Lymphocyte-HeLa cells co-culture system	20 µM	3 days	Assess whether BN@HM-OVA can reverse the inhibition of T cell proliferation caused by IDO. Results showed that BN@HM-OVA nanovaccine effectively stimulated T cell proliferation.	Bioact Mater. 2022 Mar 11;16:107-119.
CT26 colorectal tumor cells	1 µM	4 hours	Detect intracellular ROS generation, results showed significant increase in ROS upon laser irradiation	Adv Sci (Weinh). 2020 Feb 25;7(8):1903332.
HeLa cells	0–30 µM	48 hours	Evaluate the inhibitory effect of NLG-919 on IDO enzyme activity. Results showed that BN@HM-OVA nanovaccine inhibited IDO activity in a concentration-dependent manner.	Bioact Mater. 2022 Mar 11;16:107-119.
HeLa cells	50 nM–20 µM	48 hours	To evaluate the inhibitory effect of PEG2k-Fmoc-NLG on IDO activity, results showed that PEG2k-Fmoc-NLG(L) and PEG2k-Fmoc-NLG(S) could inhibit IDO activity, but were less active than free NLG919.	Nat Commun. 2016 Nov 7;7:13443.
HOS cells	10 µM	48 hours	Evaluate the anti-tumor activity of NP-Pt-IDOi on HOS cells, results showed NP-Pt-IDOi had the highest cytotoxicity and promoted apoptosis	Mater Today Bio. 2023 May 24;20:100675.
HeLa cells	50 nM –20 µM	48 hours	To test the IDO inhibitory activity of PSSN10, results showed PSSN10 blocked IDO function in a concentration-dependent manner.	Acta Pharmacol Sin. 2017 Jun;38(6):823-834.
Panc02 cells	25 μg/mL	6 hours	To evaluate intracellular H2S release and ROS production. Results showed that H2S levels and ROS signal intensity were significantly increased in SPNDNH group.	Adv Sci (Weinh). 2023 Dec;10(35):e2305150.
Human umbilical vein endothelial cells (HUVECs)	10–60 µM		Evaluate the toxicity of NCSNPs on normal cells. Results showed that NCSNPs had minimal impact on the viability of HUVECs, indicating their safety for normal cells.	Adv Sci (Weinh). 2024 May;11(20):e2305382.

Female Balb/C mice	4T1 mammary tumor model	Intraperitoneal injection	10 mg/kg	Once a day, started on day 12 and stopped on day 26 of experiments	The combination of NLG919 with PLG-CA4 and PI3Kγ inhibitor significantly suppressed the growth of breast cancer and improved the tumor suppression rate.	Adv Sci (Weinh). 2019 Apr 18;6(12):1900327
C57BL/6 mice	PANC02 pancreatic cancer model	Intravenous injection	10 mg/kg (NLG dosage)	Two injections at an interval of 2 days, followed by laser irradiation at 24 h after the second injection, and then three more injections at an interval of four days.	Evaluate the anti-tumor effect of N/PGEM/dp-16 NPs under laser irradiation. Results showed that N/PGEM/dp-16 NPs combined with laser irradiation significantly inhibited tumor growth, with negligible toxicity to liver and kidney.	Biomaterials. 2021 Feb;269:120629
C57 mice	Panc02 tumor-bearing model	Tail vein injection	16 mg/kg	Administered on the 1st, 4th, and 7th days	NLG919 improved the 5-FU-induced tumor immunosuppressive microenvironment by inhibiting the Kyn-AHR axis, enhancing the effect of chemoimmunotherapy.	J Nanobiotechnology. 2024 May 16;22(1):257
C57BL/6 mice	E.G7-OVA tumor model	Intratumoral injection	2 mg/kg per injection	Every 4 days for 3 times	Evaluate the antitumor efficacy of BN@HM-OVA nanovaccine in the E.G7-OVA tumor model. Results showed that BN@HM-OVA significantly inhibited tumor growth and prolonged survival in mice.	Bioact Mater. 2022 Mar 11;16:107-119.
C57BL/6 mice	B16F10 tumor model	Intratumoral injection	2.5 mg/kg	On Day 0, 3, and 6, total of three doses	Evaluate the antitumor efficacy of PPF NPs combined with irradiation, showing significant tumor suppression with complete tumor eradication in 30% of mice and successful rejection of a second tumor inoculation	J Nanobiotechnology. 2021 Jun 14;19(1):182
C57BL/6JGpt mice	KPC pancreatic cancer mouse model	Intravenous injection	2.8 mg/kg	Every 3 days until tumor volume reached 1500 mm³	Evaluate the antitumor efficacy of DNMCs in the KPC pancreatic cancer mouse model, results showed that DNMCs significantly inhibited tumor growth without substantial weight loss.	Mater Today Bio. 2025 Jan 13;31:101487
C57BL/6 mice	PANC02 pancreatic tumor model	Intravenous injection	20 mg/kg	Every five days for a total of 6 times	Evaluate the anti-tumor effect of PGEM carrier co-loaded with PTX and NLG919	Acta Biomater. 2020 Apr 1;106:289-300.
Mice	B16 tumor model	Intravenous injection	20 mg/kg NLG, 31.2 mg/kg SNAP	Every 2 days, duration not specified	Evaluate the antitumor efficacy of NCSNPs in the B16 tumor model. Results showed that NCSNPs significantly inhibited tumor growth and promoted immune responses.	Adv Sci (Weinh). 2024 May;11(20):e2305382.
C57BL/6 mice	Orthotopic pancreatic cancer model	Intravenous injection	200 μg/mL	Injection on day 0, 2, and 4; US irradiation on day 1, 3, and 5, repeated three times	To evaluate antitumor and anti-metastasis effects. Results showed that tumor growth was almost completely inhibited and metastasis was significantly restricted in SPNDNH+US group.	Adv Sci (Weinh). 2023 Dec;10(35):e2305150.
BALB/c mice	4T1.2 breast cancer model	Intravenous injection	25 mg/kg	Once every 3 days for 5 times	To evaluate the in vivo antitumor activity of PEG2k-Fmoc-NLG(L), results showed that PEG2k-Fmoc-NLG(L) significantly inhibited tumor growth and enhanced T-cell immune responses.	Nat Commun. 2016 Nov 7;7:13443.
Mice	Orthotopic osteosarcoma model	Intravenous injection	3.5 mg/kg Pt, 25 mg/kg NLG919	Three injections, lasting 20 days	Evaluate the anti-tumor activity of NP-Pt-IDOi in the orthotopic osteosarcoma mouse model, results showed NP-Pt-IDOi significantly inhibited tumor growth, activated the STING pathway, and remodeled the tumor microenvironment	Mater Today Bio. 2023 May 24;20:100675.
BALB/c mice	4T1 breast cancer model	Tail vein injection	4 mg/kg (Ce6 concentration) and 2.4 mg/kg (NLG919 concentration)	Every 3.5 days for a total of 4 cycles	Evaluate the therapeutic effect of NLG919@CF nanoparticles combined with anti-PD-1 antibody on breast cancer bone metastasis. Results showed that tumor volume and bone destruction were significantly reduced in the NLG919@CF + L + anti-PD-1 group.	J Nanobiotechnology. 2024 Sep 14;22(1):566
BALB/c mice	CT26 tumor-bearing mouse model	Intravenous injection	5 mg/kg	Every 5 days, total 2 times	Evaluate the antitumor effect of RIMNA in vivo, results showed that RIMNA combined with laser irradiation significantly inhibited the growth of primary and distant tumors and prolonged the survival time of mice.	J Nanobiotechnology. 2024 Sep 5;22(1):542
Balb/c mice	CT26 colorectal tumor model	Intravenous injection	5.0 mg/kg PPa and 2.6 mg/kg NLG919	Every 3 days for 3 times	Evaluate antitumor efficacy of HCNSP, results showed HCNSP+Laser significantly inhibited tumor growth and prolonged survival	Adv Sci (Weinh). 2020 Feb 25;7(8):1903332.
Female BALB/c mice	4T1 tumor model	In situ injection	5.7 mg/kg Abe and 31.8 mg/kg NLG919	Single dose, sustained for 7 days	Reduced tumor recurrence and pulmonary metastasis, prolonged survival, inhibited IDO-1 activity, increased CTL infiltration and activity	Nat Commun. 2025 Jan 15;16(1):687.
Mice	Orthotopic glioblastoma model	Oral	6 mg/mL	Continuously starting at day 7	IDO blockade synergized with chemo-radiation therapy to significantly prolong survival in mice bearing intracranial glioblastoma and triggered widespread complement deposition within tumors.	J Immunother Cancer. 2014 Jul 7;2:21
BALB/c female mice	Bilateral 4T1 tumor model	Intravenous injection	6 μmol/kg	Every two days for a total of three injections	Evaluate the inhibitory effect of PpIX-NLG@Lipo on primary and distant tumors in vivo	Theranostics. 2019 Jul 29;9(19):5542-5557
BALB/c mice	4T1 breast cancer model	Tail vein injection	6.5 mg/kg	Every 3 days, 3 times in total	To evaluate the anti-tumor effect of NLG919@Lip-pep1, results showed a tumor growth inhibition rate of 73% and significantly reduced lung metastatic nodules	Acta Pharm Sin B. 2023 May;13(5):2176-2187
Balb/c mice	Subcutaneous CT26 colon tumor model and orthotopic 4T1 breast tumor model	Intravenous injection	DOX 5 mg/kg, aNLG919 25 mg/kg	Injections at day 0, 3, and 6	To evaluate the antitumor efficacy of DNCaNPs, showing significant tumor growth suppression and extended survival	Nanomicro Lett. 2020 Nov 22;13(1):29.
BALB/c mice	4T1 breast tumor model and CT26 colorectal tumor model	Intravenous injection	NLG919 10 mg/kg, JQ1 15 mg/kg	Every 3 days for 5 doses	Assessed the antitumor efficacy and immunomodulatory effects of PHPNJ NPs, showing significant tumor growth inhibition, prolonged survival, enhanced CD8? T cell infiltration, and reduced Tregs.	Acta Pharm Sin B. 2022 Jun;12(6):2695-2709.
BALB/c mice	4T1 breast cancer model	Intravenous injection	NLG919 5 mg/kg, MSA-2 2.4 mg/kg	Every 2 days for a total of 3 times	Evaluated antitumor efficacy of MN NPs, showing significant tumor growth inhibition and immune activation	Biomater Res. 2024 Jul 4;28:0048

{[proInfo.proName]}

CAS No.: 1402836-58-1

{[proInfo.proName]}

CAS No.: 1402836-58-1

Alternative Products

Product Details of IDO-IN-7

Safety of IDO-IN-7

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	3.54mL 0.71mL 0.35mL	17.71mL 3.54mL 1.77mL	35.41mL 7.08mL 3.54mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed